Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
123I-FP-CIT + 123I-ADAM
- Development stage
- Unknown
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination of two radiopharmaceutical imaging agents. 123I-FP-CIT (ioflupane) is a cocaine analog that selectively binds to dopamine transporters (DAT) in the brain, used primarily for diagnosing Parkinsonian syndromes and differentiating between essential tremor and Parkinson's disease. 123I-ADAM selectively binds to serotonin transporters (5-HTT) in the central nervous system. Both utilize the radioactive isotope iodine-123 which has a physical half-life of 13 hours and emits gamma rays with an energy of 159 keV, making them suitable for SPECT imaging. The combination allows for assessment of both dopaminergic and serotonergic systems.
- Brand names
- DaTSCAN
- Other names
- ioflupane123I-ioflupane2-((2-((Dimethylamino)methyl)phenyl)thio)-5-123I-iodophenylamine
02
Targets
SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on 123I-FP-CIT + 123I-ADAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 123I-FP-CIT + 123I-ADAM.